1. Home
  2. ZS vs DGX Comparison

ZS vs DGX Comparison

Compare ZS & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zscaler Inc.

ZS

Zscaler Inc.

HOLD

Current Price

$117.16

Market Cap

24.7B

Sector

Technology

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$191.73

Market Cap

23.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZS
DGX
Founded
2007
1967
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.7B
23.1B
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
ZS
DGX
Price
$117.16
$191.73
Analyst Decision
Buy
Buy
Analyst Count
38
12
Target Price
$272.44
$208.92
AVG Volume (30 Days)
2.4M
646.7K
Earning Date
05-28-2026
04-21-2026
Dividend Yield
N/A
1.74%
EPS Growth
30.77
13.78
EPS
N/A
8.75
Revenue
N/A
$11,035,000,000.00
Revenue This Year
$27.83
$7.53
Revenue Next Year
$19.72
$3.77
P/E Ratio
N/A
$22.63
Revenue Growth
N/A
11.78
52 Week Low
$120.77
$160.02
52 Week High
$336.99
$213.50

Technical Indicators

Market Signals
Indicator
ZS
DGX
Relative Strength Index (RSI) 26.93 37.45
Support Level N/A $176.61
Resistance Level $164.00 $191.91
Average True Range (ATR) 7.57 4.46
MACD -1.01 -0.27
Stochastic Oscillator 8.21 10.95

Price Performance

Historical Comparison
ZS
DGX

About ZS Zscaler Inc.

Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: